
LQDA · NASDAQ
Liquidia Corporation
$47.85 +0.47 (+0.99%)
Company overview
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. The company also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $4.3B
- Employees
- 170
- Headquarters
- Morrisville, NC
- Website
- liquidia.com
- CEO
- Roger A. Jeffs
- Listed
- July 26, 2018
- P/E
- 200.33
- Dividend yield
- 0.00%
Company financials
- Revenue
- $288M
- Gross profit
- $264M
- Operating income
- $45.6M
- EBITDA
- $52M
- Net income
- $22.3M
- EPS
- $0.24
- Total assets
- $402M
- Total debt
- $185M
- Gross margin
- 91.78%
- Net margin
- 7.74%
- Earnings yield
- 0.50%
No geographic segmentation.
Showing FY 2025
News